Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

1.

The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.

Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, Markovic-Plese S.

J Immunol. 2014 Jun 15;192(12):5610-7. doi: 10.4049/jimmunol.1302580. Epub 2014 May 21.

PMID:
24850724
[PubMed - in process]
2.

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.

Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.

PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.

PMID:
24625687
[PubMed - in process]
Free PMC Article
3.

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Freedman MS, Kaplan JM, Markovic-Plese S.

J Clin Cell Immunol. 2013 Jul 8;4(4). pii: 1000152.

PMID:
24363961
[PubMed]
Free PMC Article
4.

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S.

J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.

PMID:
24198283
[PubMed - indexed for MEDLINE]
5.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
[PubMed - indexed for MEDLINE]
6.

Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.

Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S.

Eur J Immunol. 2013 Jan;43(1):281-9. doi: 10.1002/eji.201242566. Epub 2012 Dec 6.

PMID:
23076801
[PubMed - indexed for MEDLINE]
7.

Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate.

Brück W, Popescu B, Lucchinetti CF, Markovic-Plese S, Gold R, Thal DR, Metz I.

Ann Neurol. 2012 Sep;72(3):385-94. doi: 10.1002/ana.23621.

PMID:
23034911
[PubMed - indexed for MEDLINE]
8.

Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis.

Li Y, Jewells V, Kim M, Chen Y, Moon A, Armao D, Troiani L, Markovic-Plese S, Lin W, Shen D.

Hum Brain Mapp. 2013 Dec;34(12):3376-91. doi: 10.1002/hbm.22158. Epub 2012 Sep 15.

PMID:
22987661
[PubMed - indexed for MEDLINE]
9.

Pathogenic features of CD4+CD28- T cells in immune disorders.

Broux B, Markovic-Plese S, Stinissen P, Hellings N.

Trends Mol Med. 2012 Aug;18(8):446-53. doi: 10.1016/j.molmed.2012.06.003. Epub 2012 Jul 10. Review.

PMID:
22784556
[PubMed - indexed for MEDLINE]
10.

Regulation of suppressors of cytokine signaling as a therapeutic approach in autoimmune diseases, with an emphasis on multiple sclerosis.

Ramgolam VS, Markovic-Plese S.

J Signal Transduct. 2011;2011:635721. doi: 10.1155/2011/635721. Epub 2011 Nov 1.

PMID:
22132325
[PubMed]
Free PMC Article
11.

CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients.

Broux B, Pannemans K, Zhang X, Markovic-Plese S, Broekmans T, Eijnde BO, Van Wijmeersch B, Somers V, Geusens P, van der Pol S, van Horssen J, Stinissen P, Hellings N.

J Autoimmun. 2012 Feb;38(1):10-9. doi: 10.1016/j.jaut.2011.11.006. Epub 2011 Nov 26.

PMID:
22123179
[PubMed - indexed for MEDLINE]
12.

Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.

Zhang X, Tao Y, Troiani L, Markovic-Plese S.

J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.

PMID:
21856936
[PubMed - indexed for MEDLINE]
Free Article
13.

A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases.

Sha Y, Markovic-Plese S.

Self Nonself. 2011 Jan;2(1):35-42. Epub 2011 Jan 1.

PMID:
21776333
[PubMed]
Free PMC Article
14.

Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Meeker RB, Poulton W, Markovic-Plese S, Hall C, Robertson K.

J Neurovirol. 2011 Jun;17(3):258-73. doi: 10.1007/s13365-011-0034-5. Epub 2011 May 10.

PMID:
21556959
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.

Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S.

J Immunol. 2011 Apr 1;186(7):4518-26. doi: 10.4049/jimmunol.1000271. Epub 2011 Mar 2.

PMID:
21368231
[PubMed - indexed for MEDLINE]
Free Article
16.

T cell LFA-1 engagement induces HuR-dependent cytokine mRNA stabilization through a Vav-1, Rac1/2, p38MAPK and MKK3 signaling cascade.

Ramgolam VS, DeGregorio SD, Rao GK, Collinge M, Subaran SS, Markovic-Plese S, Pardi R, Bender JR.

PLoS One. 2010 Dec 29;5(12):e14450. doi: 10.1371/journal.pone.0014450.

PMID:
21206905
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.

Zhang X, Markovic-Plese S.

Clin Neurol Neurosurg. 2010 Sep;112(7):641-5. doi: 10.1016/j.clineuro.2010.04.020. Epub 2010 Jun 1. Review.

PMID:
20570038
[PubMed - indexed for MEDLINE]
18.

Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.

Ramgolam VS, Markovic-Plese S.

Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):161-7. Review.

PMID:
20384573
[PubMed - indexed for MEDLINE]
19.

IFN-beta inhibits human Th17 cell differentiation.

Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S.

J Immunol. 2009 Oct 15;183(8):5418-27. doi: 10.4049/jimmunol.0803227. Epub 2009 Sep 25.

PMID:
19783688
[PubMed - indexed for MEDLINE]
Free Article
20.

Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys.

Buie LK, Rasmussen CA, Porterfield EC, Ramgolam VS, Choi VW, Markovic-Plese S, Samulski RJ, Kaufman PL, Borrás T.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):236-48. doi: 10.1167/iovs.09-3847. Epub 2009 Aug 13.

PMID:
19684004
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk